Cancer Clinical Trials Information Platform in Hong Kong


  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials


Cancer Site


*in alphabetical order (Last updated on 6/11/2020)


Liver Cancer

Institution Study Title  
CUHK A study to evaluate the impact of liver stiffness on treatment outcome of unresectable hepatocellular carcinoma Click for Details
CUHK Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib Click for Details
CUHK A clinical trial of pembrolizumab inpatients with hepatitis B virus-related hepatocellular carcinoma, with parallel study on baseline and serial change in the immune environment Click for Details
CUHK A Phase 3, Randomized, Double-blind Study ofAdjuvant Nivolumab versus Placebo for Participants with HepatocellularCarcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resectionor Ablation Click for Details
CUHK A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy Click for Details
CUHK A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or local Ablation (KEYNOTE-937) Click for Details
CUHK Study on the clinical role of the Albumin-Bilirubin-index (ALBI) in patients treated with lenvatinib for hepatocellular carcinoma Click for Details
CUHK A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy Click for Details
CUHK A phase iii, multicenter, randomized, open-labelstudy of atezolizumab (anti-pd-l1 antibody) plus bevacizumab versus activesurveillance as adjuvant therapy in patients with hepatocellular carcinoma athigh risk of recurrence after surgical resection or ablation Click for Details
CUHK A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination with Brivamib Alaninate (Zl-2301) in Patients with Advanced Liver Cancer Click for Details
CUHK Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) Click for Details
PYNEH Randomized phase III study of sorafenib versus Stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma [RTOG 1112] Click for Details
QMH Prospective Study of Stereotactic Body Radiation Therapy as Bridging Therapy for Hepatocellular Carcinoma Patients on Waiting List for Liver Transplantation [SBRT for HCC] Click for Details
QEH Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib [Protocol no.: I4T-MC-JVDE] Click for Details


For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.